SOPHiA GENETICS

TLDR

SOPHiA GENETICS is a publicly traded genomics and data-driven medicine company with Belgian roots and Swiss operations, backed by Alychlo, that applies AI to clinical genomic data analysis.

Overview

SOPHiA GENETICS built a platform that enables hospitals and clinical labs to analyze genomic data and derive actionable clinical insights. The platform is used for oncology diagnostics, rare disease identification, and pharmacogenomics across a global hospital network.

The company has a dual Belgian and Swiss identity, reflecting its founding roots and operational base. Alychlo, the investment vehicle of Marc Coucke, holds a position in the company. SOPHiA GENETICS is publicly traded, making it one of the Belgian ecosystem's notable public market outcomes in the life sciences and AI intersection.

Key People

• Jurgi Camblong - Founder and CEO